Clinical Trials Search | Clareo Health

Showing 1-1 of 1 trials

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

NCT07250477

This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.

Non-small Cell Lung Cancer Stage IIICNon-small Cell Lung Cancer Stage IVNon Small Cell Lung Cancer+2 more

University of California, Davis56 participantsStarted Jan 2026

Sacramento, California, United States

Data from ClinicalTrials.govTerms

Filters

Filters

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer